Mangalam Drugs And Organics Limited has informed the Exchange regarding Board meeting held on August 07, 2025.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mangalam Drugs and Organics reported its Q1 FY26 results (quarter ended June 30, 2025) on August 7, 2025, swinging to a standalone net loss of Rs 1,372.80 lakhs from a profit of Rs 268.47 lakhs in the same quarter last year. Total income from operations fell about 25% to Rs 5,734.87 lakhs (vs Rs 7,653.62 lakhs in Q1 FY25), while total expenses remained elevated at Rs 6,623.26 lakhs, driven by material, employee, finance, and other costs. The loss before tax stood at Rs 1,292.80 lakhs, resulting in a negative EPS of Rs (8.67). On a consolidated basis, the net loss was Rs 1,379.83 lakhs with EPS of Rs (8.72). The statutory auditors gave an unmodified (clean) limited review report. The board also noted that the pending scheme of merger with Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd has an NCLT meeting for shareholders and creditors scheduled for August 12, 2025.
The sharp swing to a sizeable quarterly loss, driven by a 25% revenue drop and sticky costs, is a clear negative for the stock and is likely to weigh on near-term sentiment. Investors should watch the August 12, 2025 NCLT outcome on the proposed merger as the next key catalyst.